FDA Clearance Tracker · P030047-S049
PRECISE PRO RX Transcarotid Stent System
Last checked: Nov 20, 2026Latest source record: Apr 4, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Apr 4, 2025
Approved
Time to decision
185 days
Received Oct 1, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P030047-S049
- Device name
- PRECISE PRO RX Transcarotid Stent System
- Applicant
- Cordis US Corporation
- Applicant location
- Miami Lakes, FL
- Received
- Oct 1, 2024
- Decided
- Apr 4, 2025
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P030047
Device type
- Device type
- Stent, carotid (NIM)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
The PRECISE® PRO Transcarotid Stent System used in conjunction with the ENROUTE® Transcarotid Neuroprotection System (NPS), is indicated for the treatment of patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet the criteria outlined below.1. Patients with neurological symptoms and >= 50% stenosis of the common or internal carotid artery by ultrasound or angiogram OR patients without neurological symptoms and >= 80% stenosis of the common or internal carotid artery by ultrasound or angiogram, AND2. Patients must have a vessel diameter of 4-9 mm at the target lesion,AND 3. Carotid bifurcation is located at minimum 5cm above the clavicle to allow for placement of the ENROUTE Transcarotid NPS.
Source documents
Other decisions for Cordis US Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P040044-S097 · Decided Jun 27, 2024 · 210 days after receipt · Panel Track
Device type: Device, hemostasis, vascular (MGB) · Cardiology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.